Cognitive Impairment and Fatigue After Mild to Moderate COVID-19

Summary

The primary aim of the project is to map fatigue, cognitive and visual dysfunctions and possible underlying pathophysiological mechanisms in persons with long-term symptoms after a mild to moderate COVID-19 infection. Secondary goals are to study whether covarying factors such as depression and sleep disorders contribute to the results.

Conditions

• Post COVID-19 Condition
• Cognitive Impairment
• Fatigue, Mental

Interventions

DIAGNOSTIC_TEST

Neuropsychological investigation

Comprehensive neuropsychological test battery covering logical reasoning, different attention functions, executive functions, visuospatial functions, different memory functions, psychomotor speed, motor functions, and smell identification

DIAGNOSTIC_TEST

Optometric investigation

Extended vision examination including symptom assessment, visual acuity, visual field (confrontation), eye movements, eye teaming and clinical assessment of hypersensitivity to visual stimuli.

DIAGNOSTIC_TEST

Magnetic Resonance Imaging

The MRI sequence protocol includes resting state fMRI before and after the participants do an established 20 min long reaction time measurement paradigm (E-prime). During the paradigm a pseudo-continious arterial spin labeling sequence (pCASL) is acquired for continuous measurement of brain perfusion. Following the functional sequences the imaging protocol also includes a high resolution 3D T1weighted sequence Magnetization Prepared Rapid Gradient Echo (MPRAGE) for brain structure, a high resolution 3D T2-weighted sequence Fluid-Attenuated Inversion Recovery (FLAIR) for pathology and a 3D susceptibility weighted image (SWI) for microvascular abnormalities.

DIAGNOSTIC_TEST

Immunological biomarkers

Venous blood samples (10-20 ml) are taken from the elbow crease. They are drawn in the morning, and the participants are asked to fast for 12 hours prior to sampling. They are also asked to avoid physical activity prior to blood sampling. The samples are drawn into citrated tubes.

Sponsors & Collaborators

• Karolinska Institutet

  collaborator OTHER

• Karolinska University Hospital

  collaborator OTHER

• Uppsala University Hospital

  collaborator OTHER

• Danderyd Hospital

  lead OTHER

Principal Investigators

• Kristian Borg, Professor · Karolinska Institutet

• Marika C Möller, PhD · Department of Rehabilitation Medicine, Danderyd University Hospital

Eligibility

Min Age

18 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2021-04-01

Primary Completion

2025-12-31

Completion

2025-12-31

Countries

• Sweden

Study Locations